Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2018 16:05 ET | Source: Axovant Sciences Ltd.

Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates

First patient dosed in clinical study of AXO-Lenti-PD, a novel gene therapy for treatment of Parkinson’s diseaseExpanded pipeline of gene therapies with in-licensing of AXO-AAV-OPMD for treatment of...
October 25, 2018 02:00 ET | Source: Axovant Sciences Ltd.

Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease

Initial data from the first cohort expected in first half of 2019 BASEL, Switzerland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a company developing innovative gene...
October 09, 2018 09:02 ET | Source: Axovant Sciences Ltd.

Axovant Announces Data to be Presented at the Annual Congress of the European Society of Gene and Cell Therapy

BASEL, Switzerland, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a gene therapy company developing innovative treatments for debilitating neurologic and neuromuscular diseases,...
September 20, 2018 07:00 ET | Source: Axovant Sciences Ltd.

Axovant to Present at Two Upcoming Investor Conferences

BASEL, Switzerland, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the...
August 29, 2018 07:00 ET | Source: Axovant Sciences Ltd.

Axovant to Present at Upcoming Investor Conferences

BASEL, Switzerland, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will participate in two upcoming investor...
August 07, 2018 16:05 ET | Source: Axovant Sciences Ltd.

Axovant Announces First Fiscal Quarter 2018 Financial Results and Corporate Update

Pipeline expanded with gene therapy technologies including AXO-Lenti-PD for treatment of Parkinson’s Disease and AXO-AAV-OPMD for treatment of oculopharyngeal muscular dystrophy Ilise Lombardo, MD,...
July 08, 2018 20:18 ET | Source: Axovant Sciences Ltd.

Axovant Announces Global Licensing Agreement for AXO-AAV-OPMD Program for Treatment of Oculopharyngeal Muscular Dystrophy and Broader Platform Collaboration with Benitec Biopharma

License grants Axovant worldwide rights to AXO-AAV-OPMD utilizing proprietary Silence-and-Replace technology, which suppresses mutant protein production while restoring expression of functional...
June 18, 2018 08:30 ET | Source: Axovant Sciences Ltd.

Axovant to Present at First Annual Roivant Pipeline Day

BASEL, Switzerland, June 18, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the first...
June 06, 2018 02:00 ET | Source: Axovant Sciences Ltd.

Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition

Exclusive worldwide license to lentiviral vector gene therapy constitutes the first transaction of Axovant’s 2018 pipeline expansionFraser Wright, Co-Founder and former Chief Technology Officer of...
May 31, 2018 07:00 ET | Source: Axovant Sciences Ltd.

Axovant to Present at Two Upcoming Investor Conferences

BASEL, Switzerland, May 31, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON) today announced that Pavan Cheruvu, M.D., chief executive officer, will present a corporate overview at the...